Enanta Pharmaceuticals misses Q4 revenue estimates, posts wider net loss
ENTA•Enanta Pharmaceuticals reported fiscal fourth-quarter revenue of $12.87 million, below the $14.20 million analyst estimate, and a net loss of $23.72 million, wider than $18.7 million a year earlier. The company expects its cash and marketable securities to fund operations into fiscal 2029.
1. Quarterly results
Fiscal fourth-quarter revenue fell short of analyst expectations at $12.87 million, while net loss widened to $23.72 million from $18.7 million. Enanta said lower royalties from AbbVie’s sales of MAVYRET/MAVIRET contributed to the revenue decline, and higher research and development expenses reflected increased costs for its RESOLVE and LOTUS RSV trials.
2. Trial and cash outlook
Enanta expects topline data from its pediatric LOTUS RSV trial in the first quarter of 2027 and from its adult RESOLVE RSV trial in 2027. It expects cash and marketable securities to fund operations into fiscal 2029; the company cut its workforce by about one-third in September to boost efficiency and extend its cash runway.




